Show simple item record

dc.contributor.authorLapatto, Helena A. K.
dc.contributor.authorKuusela, Minna
dc.contributor.authorHeikkinen, Aino
dc.contributor.authorMuniandy, Maheswary
dc.contributor.authorvan der Kolk, Birgitta W.
dc.contributor.authorGopalakrishnan, Swetha
dc.contributor.authorPöllänen, Noora
dc.contributor.authorSandvik, Martin
dc.contributor.authorSchmidt, Mark S.
dc.contributor.authorHeinonen, Sini
dc.contributor.authorSaari, Sina
dc.contributor.authorKuula, Juho
dc.contributor.authorHakkarainen, Antti
dc.contributor.authorTampio, Janne
dc.contributor.authorSaarinen, Tuure
dc.contributor.authorTaskinen, Marja-Riitta
dc.contributor.authorLundbom, Nina
dc.contributor.authorGroop, Per-Henrik
dc.contributor.authorTiirola, Marja
dc.contributor.authorKatajisto, Pekka
dc.contributor.authorLehtonen, Marko
dc.contributor.authorBrenner, Charles
dc.contributor.authorKaprio, Jaakko
dc.contributor.authorPekkala, Satu
dc.contributor.authorOllikainen, Miina
dc.contributor.authorPietiläinen, Kirsi H.
dc.contributor.authorPirinen, Eija
dc.date.accessioned2023-01-25T06:27:14Z
dc.date.available2023-01-25T06:27:14Z
dc.date.issued2023
dc.identifier.citationLapatto, H. A., Kuusela, M., Heikkinen, A., Muniandy, M., van der Kolk, B. W., Gopalakrishnan, S., Pöllänen, N., Sandvik, M., Schmidt, M. S., Heinonen, S., Saari, S., Kuula, J., Hakkarainen, A., Tampio, J., Saarinen, T., Taskinen, M.-R., Lundbom, N., Groop, P.-H., Tiirola, M., . . . Pirinen, E. (2023). Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. <i>Science Advances</i>, <i>9</i>(2), Article eadd5163. <a href="https://doi.org/10.1126/sciadv.add5163" target="_blank">https://doi.org/10.1126/sciadv.add5163</a>
dc.identifier.otherCONVID_172653171
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/85165
dc.description.abstractNicotinamide adenine dinucleotide (NAD+) precursor nicotinamide riboside (NR) has emerged as a promising compound to improve obesity-associated mitochondrial dysfunction and metabolic syndrome in mice. However, most short-term clinical trials conducted so far have not reported positive outcomes. Therefore, we aimed to determine whether long-term NR supplementation boosts mitochondrial biogenesis and metabolic health in humans. Twenty body mass index (BMI)–discordant monozygotic twin pairs were supplemented with an escalating dose of NR (250 to 1000 mg/day) for 5 months. NR improved systemic NAD+ metabolism, muscle mitochondrial number, myoblast differentiation, and gut microbiota composition in both cotwins. NR also showed a capacity to modulate epigenetic control of gene expression in muscle and adipose tissue in both cotwins. However, NR did not ameliorate adiposity or metabolic health. Overall, our results suggest that NR acts as a potent modifier of NAD+ metabolism, muscle mitochondrial biogenesis and stem cell function, gut microbiota, and DNA methylation in humans irrespective of BMI.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherAmerican Association for the Advancement of Science (AAAS)
dc.relation.ispartofseriesScience Advances
dc.rightsCC BY 4.0
dc.titleNicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202301251459
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.oppiaineResurssiviisausyhteisöfi
dc.contributor.oppiaineNanoscience Centerfi
dc.contributor.oppiaineLiikuntalääketiedefi
dc.contributor.oppiaineYmpäristötiedefi
dc.contributor.oppiaineSchool of Resource Wisdomen
dc.contributor.oppiaineNanoscience Centeren
dc.contributor.oppiaineSports and Exercise Medicineen
dc.contributor.oppiaineEnvironmental Scienceen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn2375-2548
dc.relation.numberinseries2
dc.relation.volume9
dc.type.versionpublishedVersion
dc.rights.copyright© 2023 the Authors
dc.rights.accesslevelopenAccessfi
dc.relation.grantnumber308042
dc.subject.ysomitokondriot
dc.subject.ysolihavuus
dc.subject.ysoaineenvaihdunta
dc.subject.ysoterveysvaikutukset
dc.subject.ysoylipaino
dc.subject.ysoaineenvaihduntahäiriöt
dc.subject.ysosuolisto
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p21158
jyx.subject.urihttp://www.yso.fi/onto/yso/p823
jyx.subject.urihttp://www.yso.fi/onto/yso/p3066
jyx.subject.urihttp://www.yso.fi/onto/yso/p15449
jyx.subject.urihttp://www.yso.fi/onto/yso/p826
jyx.subject.urihttp://www.yso.fi/onto/yso/p6239
jyx.subject.urihttp://www.yso.fi/onto/yso/p10317
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1126/sciadv.add5163
dc.relation.funderResearch Council of Finlanden
dc.relation.funderSuomen Akatemiafi
jyx.fundingprogramAcademy Research Fellow, AoFen
jyx.fundingprogramAkatemiatutkija, SAfi
jyx.fundinginformationThis work was supported by Centre of Excellence funding from the Academy of Finland (#272376 to K.H.P. and #336823 to J.Ka.), Academy of Finland grants (286359, 314455, 335445, and Profi6 336449 to E.P.; 335443, 314383, 272376, and 266286 to K.H.P.; 308042 to S.P.; 308042 and 328685 to M.O.),Sigrid Jusélius Foundation (to K.H.P.), Finnish Medical Foundation (to H.A.K.L. and N.P.), Medical Society of Finland (to H.A.K.L.), Biomedicum Helsinki Foundation (to N.P.), Finnish Diabetes Research Foundation (to E.P.), Novo Nordisk Foundation (NNF20OC0060547, NNF17OC0027232, and NNF10OC1013354 to K.H.P.), Gyllenberg Foundation (to K.H.P.), Government Research Funds to Helsinki University Hospital (to K.H.P.), National Institutes of Health (R01HL147545 to C.B.), and Alfred E. Mann Family Foundation (to C.B.)
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0